Opus Genetics is trading at $4.29 (+5.93%) in pre-market, with no clear company-specific catalyst identified.
- No clear company-specific announcement was found for August 24, 2026; latest listed releases include inducement grants and earlier financial results.
- Recent second-quarter results showed $755,000 revenue versus a $2.63 million consensus estimate, making the report a stale and mixed catalyst.
- Broader U.S. futures are mixed-to-lower, so market sentiment does not clearly explain the move.